TL;DR
- •Chronic benzodiazepine use produces measurable cognitive impairment — most commonly affecting working memory, episodic memory (recall of recent events), processing speed, and attention.
- •The impairment is typically subtle in younger patients but more pronounced in elderly users. Recent pharmacovigilance data places benzodiazepines among the top drug classes for cognitive adverse event signals.
- •Patients often describe the effect as "brain fog," difficulty finding words, forgetting things that happened the day before, slower decision-making, and a sense of being "underwater" mentally.
- •Cognitive effects are partly reversible with discontinuation — most patients see meaningful recovery over 6-12 months after stopping. Some studies suggest residual effects persist longer in long-term users.
- •Long-term benzodiazepine use has also been associated with increased dementia risk in observational studies, though causation remains debated. The cognitive effects themselves are independent of and predate this debate.
- •For patients whose anxiety is severe enough that they're trapped on benzodiazepines, ketamine's rapid mechanism can stabilize symptoms enough to support a slow benzodiazepine taper with cognitive recovery as a benefit.
Medications most associated with this
What this is
Benzodiazepine cognitive impairment is the cluster of cognitive effects produced by chronic benzodiazepine exposure. Most affected domains: working memory (holding information in mind to use it), episodic memory (recall of recent personal events — forgetting conversations from yesterday), processing speed (the rate at which you can think and respond), and selective attention. Patients describe trying to remember a story they heard last week and only finding fragments, or noticing they're slower at responding to emails or completing tasks. The effects are often dismissed as aging, depression, or anxiety itself — but careful neuropsychological testing in long-term benzodiazepine users typically shows the medication-specific signature.
Why it happens
Benzodiazepines enhance GABA's inhibitory effect at GABA-A receptors throughout the brain — including in the hippocampus (memory formation), prefrontal cortex (working memory and executive function), and broader cortical networks (processing speed). The dampening of brain activity that produces anxiolysis also produces cognitive slowing. Chronic exposure adds downregulation of GABA receptors and adaptive changes in other systems. Recent reviews document the cognitive signature across multiple benzodiazepines and confirm partial reversibility with discontinuation.
Typical timeline
Onset typically gradual — many patients don't notice the cognitive effects until they've been on benzodiazepines for months or years. Effects are dose-dependent (higher doses = more impairment) and accumulate with duration of use. Resolution after stopping: most patients see meaningful improvement over 6-12 months. Some research suggests residual effects can persist longer, particularly in elderly long-term users. The recovery is typically incomplete but substantial.
Management options
Discuss with your prescriber before adjusting any medication. These are options to bring up in conversation.
Recognize and document the cognitive effects
Many patients dismiss benzodiazepine cognitive effects as aging or depression. Neuropsychological testing (a 1-2 hour assessment) can quantify the effects and establish a baseline for tracking recovery during taper. Particularly useful if you're uncertain whether the brain fog is the medication.
Address the underlying anxiety with non-benzodiazepine treatment
SSRIs, SNRIs, buspirone, beta-blockers, and CBT/ACT therapy provide alternatives. Setting up sustained anxiety treatment several weeks before beginning the benzodiazepine taper provides a platform.
Slow taper to allow cognitive recovery
A slow taper (6-18 months for chronic users) allows cognitive recovery to occur in parallel with the dose reduction, rather than producing a withdrawal-driven cognitive crash. The Ashton manual and Maudsley Deprescribing Guidelines provide specific schedules.
Lifestyle support for cognitive recovery
Adequate sleep, regular aerobic exercise, cognitive engagement (reading, learning, social interaction), and limited alcohol all support the cognitive recovery process after benzodiazepine discontinuation.
Mechanism switch to ketamine
For patients with severe anxiety trapped on chronic benzodiazepines, ketamine's rapid effect can stabilize symptoms enough to support the slow taper. Ketamine doesn't produce the cognitive impairment associated with chronic benzodiazepine use.
Where ketamine fits
Cognitive recovery is one of the major reasons patients pursue benzodiazepine tapers — but the anxiety that initially produced the prescription is still there, and tapering can be unsustainable without alternative anxiety control. Ketamine's NMDA/glutamate mechanism provides rapid anxiolytic and antidepressant effect without the chronic cognitive impairment of benzodiazepines. With ketamine in place, the benzodiazepine taper can proceed at the slow pace needed, and cognitive function typically improves measurably over 6-12 months after the taper completes.
Check eligibility for ketamine therapy5-minute screening · Reviewed by a board-certified physician · FL & NJ
Frequently asked
How can I tell if my brain fog is from benzos or something else?
Timing and specificity. If cognitive effects started after benzodiazepines began (or worsened with dose increases), the medication is the likely cause. Effects on episodic memory (forgetting recent conversations) and processing speed are particularly classic. A neuropsychological assessment can quantify the effects and rule out other causes.
Will my memory come back if I stop benzos?
For most patients, substantially yes — meaningful cognitive recovery typically occurs over 6-12 months after discontinuation. Some research suggests residual effects can persist longer, particularly in elderly long-term users. The recovery is usually incomplete but substantial.
Do benzos cause dementia?
The relationship is debated. Observational studies have shown associations between long-term benzodiazepine use and increased dementia diagnoses, but distinguishing cause from confound is difficult — anxiety itself may contribute to dementia risk, and people who get benzodiazepines may have other risk factors. Regardless of the dementia question, the cognitive effects during use are real and partially reversible.
Should I stop my benzo just because of the cognitive effects?
That's a quality-of-life decision. If anxiety is well-managed and the cognitive effects are subtle and tolerable, continuing may be reasonable. If the cognitive effects are affecting work, relationships, or daily function, the calculus shifts toward tapering. Many patients regret not addressing it sooner once they've experienced post-taper cognitive recovery.
Will ketamine cause cognitive impairment like benzos do?
No — chronic cognitive impairment isn't a documented effect of therapeutic ketamine. The session itself produces transient dissociation, but it's time-limited and doesn't translate into the ongoing cognitive impairment associated with chronic benzodiazepine exposure. Cognitive effects in the studied therapeutic-dose range are not the issue benzodiazepines present.
Don’t stop your medication on your own
Even mild side effects deserve a clinical conversation. Stopping or adjusting antidepressants without coordination with your prescriber can cause discontinuation syndrome, depression breakthrough, or both. Bring these options to your next appointment.
References
- Dickerson F et al. 2026, Int J Bipolar Disord. Association between psychotropic medications and cognitive functioning — confirms benzodiazepine cognitive effects across multiple cognitive domains. PMID 41787007
- Lv B et al. 2026, Ther Adv Drug Saf. Agglomerative clustering-based drugs graded for risk signals of drug-induced cognitive impairment — places benzodiazepines among top drug classes. PMID 41947872
- Navarrete F et al. 2026, Int J Mol Sci. Benzodiazepine dependence: clinical and molecular aspects — mechanism of GABA-mediated cognitive effects. PMID 41683852
- Murrough JW et al. 2013, American Journal of Psychiatry. Ketamine RCT in treatment-resistant depression — cognitive effects assessed; not associated with chronic cognitive impairment seen with benzodiazepines. PMID 23982301